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Abstract: Transarterial chemoembolization (TACE) is commonly used for the treatment of locally advanced hepa-
tocellular carcinoma (HCC) by its dual effects of chemotherapy and ischemic hypoxia. However, one of the side 
effects of TACE is the introduction of hypoxic condition, which in turn activates hypoxia-induced survival pathways 
and enhances VEGF-induced neovascularization by stabilizing HIF-1α expression. Herein, the preclinical therapeutic 
efficacy of the combined treatment of everolimus, a novel mTOR inhibitor and TACE for the treatment of HCC was in-
vestigated. The MHCC-97L cells were used for the study of the effect of combined treatment on cell proliferation and 
cellular apoptosis. HUVEC cells were used for the study on tube formation under different treatments. Inhibitions 
on the Akt/mTOR pathways were also studied. Finally, the effect on tumor growth was further study using an in vivo 
orthotopic model. The results demonstrated that everolimus enhanced the therapeutic efficacy of TACE in inhibiting 
cell proliferation, promoting apoptosis and inhibiting tube formation of endothelial cells by blocking the Akt/mTOR 
signaling pathway in vitro and inhibiting tumor growth and neoangiogenesis in vivo. Based on this preclinical study, 
the potential of combining everolimus with TACE was guaranteed which suggested the use of the combination 
therapy in the clinical treatment of advanced HCC patients.
Keywords: Everolimus, hepatocellular carcinoma, hypoxia, mTOR signaling pathway, transarterial chemoemboliza-
tion, tumor growth
Introduction
Hepatocellular carcinoma (HCC) is the fifth 
most common cancer worldwide [1]. Surgery 
for HCC including partial liver resection and 
liver transplantation remains the most effec-
tive treatment for HCC. However, only a minority 
of HCC patients are eligible to the surgical 
treatment and poor prognosis with high recur-
rence rate is always observed [2-4]. In addition, 
adjuvant systemic chemotherapy has not been 
shown to be beneficial in HCC patients due to 
the chemoresistance of HCC cells and poor tol-
erance and side effects of anti-tumor drugs to 
cirrhotic patients [2, 5]. Therefore, it is worth-
while to develop more efficient treatment for 
unresectable HCC patients. 
Transarterial chemoembolization (TACE) is 
commonly used for the treatment of unresect-
able HCC. It is done by injecting an embolic par-
ticles coated with chemotherapeutic agents 
such as cisplatin into the hepatic artery. It then 
works by blocking the blood supply to the tumor 
as well as delivering chemotherapeutic drug 
directly to the tumor. TACE was found to prolong 
the overall survival of patients with unresect-
able HCC compared with conservative treat-
ment in two randomized trials [6, 7]. However, 
some studies showed that TACE cannot com-
pletely eliminate the risk of a recurrence [8, 9]. 
In addition, blocking the blood supply induces 
hypoxic condition, which in turn stabilizes the 
hypoxia inducible factor 1α (HIF-1α) protein. 
HIF-1α activates the transcription of genes that 
are involved in angiogenesis, cell survival, and 
cell migration and invasion which are crucial to 
cancer growth and recurrence [10]. Therefore, 
there is still room for improvement to enhance 
the tumor eliminating effect of TACE in order to 
prevent recurrence in HCC. 
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The mammalian target of rapamycin (mTOR) is 
a serine/threonine kinase and member of the 
phosphoinositide 3-kinase (PI3K)-related kin- 
ase family. It integrates and transmits signals 
from a diverse array of signaling pathways to 
regulate cell survival and growth [11]. mTOR 
exists in two complexes, mTORC1 and mTORC2, 
which controls cell growth and cell survival, 
respectively. Several reports have indicated 
that mTOR is a positive regulator of hypoxia 
inducible factor 1 (HIF-1) expression and activi-
ty [12], and the inhibition of HIF-mediated gene 
expression is considered to be related to the 
anti-tumor activity of mTOR inhibitors [13]. In 
addition, HIF-1 activates vascular endothelial 
growth factor (VEGF) gene expression [14]. 
Therefore, the Akt/mTOR signaling pathway is 
also important in regulating neovascularization 
which is a crucial factor for the success of TACE 
treatment [15].
Everolimus is an mTOR inhibitor which is cur-
rently used as an immunosuppressant [16-18] 
and as a molecular targeting drug in cancers 
such as renal cell carcinoma and breast cancer. 
Our previous study has demonstrated that 
everolimus suppressed HCC tumor growth and 
sensitized tumor cells to cisplatin-induced cyto-
toxicity [19]. Therefore, we hypothesized that 
everolimus enhances the therapeutic efficacy 
of TACE by inhibiting the mTOR mediated HIF-1 
expression and sensitizing the cisplatin effect 
on HCC tumor cells. The combination effect of 
everolimus and cisplatin under hypoxic condi-
tion was first studied by in vitro experiments. 
We then mimicked the TACE treatment using a 
mouse orthotopic HCC model by hepatic artery 
ligation (HAL) and intraprotal vein injection of 
cisplatin. The effect of everolimus on this in 
vivo model was then investigated. Therefore, 
with this study, the pre-clinical enhancing effect 
of everolimus on TACE treatment can be dem-
onstrated which provides the basis for future 
clinical practice of everolimus on TACE 
treatment.
Materials and methods
Drugs and reagents 
Everolimus was kindly provided by Novartis 
Pharmaceuticals Corporation. All reagents 
were purchased from Sigma-Aldrich (St. Louis, 
MO) unless specified below. 
Cell culture and treatment
MHCC97L cells (Liver Cancer Institute, Fudan 
University) were maintained in DMEM (Life 
Technologies, Carlsbad, CA) supplemented with 
10% heat-inactivated fetal bovine serum (Life 
Technologies) and 1% penicillin/streptomycin 
(Life Technologies) at 37°C in a humidified 5% 
CO2 atmosphere. MHCC97L cells were stably 
transfected with luciferase expressing con-
struct for the ease of detection in the in vivo 
study. Human umbilical vein endothelial cells 
(HUVEC; Life Technologies) were grown in a 
complete endothelial growth medium (Life 
Technologies) and were used between passag-
es 4-6. 
For the in vitro study, cells were treated as 1) 
Control group: in normoxic condition (20% O2, 
5% CO2 and 75% N2) without any drug treat-
ment, 2) Hypoxia group: in hypoxic condition 
(1% O2, 5% CO2 and 94% N2) maintained in an 
OxyCycler C42 hypoxia chamber (Biospherix, 
St. Lacona, NY), 3) Hypoxia + C group: in hypox-
ic condition and 6 μM cisplatin, 4) Hypoxia + E 
group: in hypoxic condition and 10 nM everoli-
mus, and 5) Hypoxia + C + E group: in hypoxic 
condition, 6 μM cisplatin and 10 nM 
everolimus. 
Cell proliferation assay
The treatment effect on MHCC97L cells was 
first examined by MTT assay as previously 
described [20]. Briefly, cells were plated in 
96-well culture plates for 24 hours and media 
were replaced with the treatment media with 
increasing concentrations of everolimus (0 to 
100 nM) under normoxia, hypoxia or hypoxia 
with 6 μM cisplatin. After 72 hours, viability was 
assessed with the replacement of treatment 
media with MTT solution (1 mg/ml) (Life 
Technologies) and the average readings of the 
absorbance at 570 nm from 3 replicates of 
each treatment were determined. 
Apoptosis assay
After MHCC97L cells were treated for 48 hours, 
cells were harvested, washed with ice-cold 
PBS, and stained with annexin V-FITC antibody 
(BD Biosciences Pharmingen). The percentage 
of apoptotic cells (annexin V positive cells) were 
determined by flow cytometry using the 
Cytomics FC500 Analyzer (Beckman-Coulter, 
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CA). Unstained cells were used as a negative 
control.
Tube formation assay
The tube formation ability of the HUVEC cells 
was determined by the Endothelial Cell Tube 
Formation Assay (Life technologies) according 
to the manufacturer’s instructions. The bot-
toms of a 96-well plate were first coated with 
Geltrex™ Reduced Growth Factor Basement 
Membrane Matrix and 5 × 104 HUVEC cells 
were seeded on the surface of the gel and after 
treatment for 6 h, cells were stained with 
Calcein AM (Life technologies) and assessed 
under a fluorescence microscope (400 × 
magnification).
Multiplex bead assay
After MHCC97L cells were treated for 24 hours, 
cells were harvested and washed in ice-cold 
PBS. The expression levels of phosphorylated 
mTOR (Ser2448), p70S6K (Thr412), RPS6 
(Ser235/Ser236), Akt (Ser473), TSC2 (Ser939), 
GSK3α (Ser21), GSK3β (Ser9), and p53 (Ser15) 
were quantified using a bead-based MILLI- 
PLEX® multiplex assay (Millipore, Billerica, MA) 
according to the manufacturer’s instructions. 
Briefly, cells were lysed in MILLIPLEX MAP lysis 
buffer and diluted with an equal volume of 
MILLIPLEX MAP cell assay buffer. Capture anti-
body beads were diluted in MILLIPLEX MAP cell 
assay buffer and added to a Beadlike filter 
plate. 25 μl of the diluted cell lysate was then 
transferred to each well of the filter plate and 
incubated for 2 h at room temperature with 
shaking. After incubation, the beads were 
washed twice with cell assay buffer, and bioti-
nylated detection antibodies diluted in cell 
assay buffer were added and incubated for 1 h 
at room temperature with shaking. After filter-
ing, MILLIPLEX MAP streptavidin-phycoerythrin 
solution was added and incubated for 30 min 
at room temperature with shaking. Finally, cell 
assay buffer was added after filtering, and sig-
nals were read using the Bio-Plex Luminex 200 
system (Bio-Rad, Hercules, CA). The fluores-
cence signal of each phosphorylated protein 
was normalized with that of GAPDH. 
Immunoblotting
After treatment, cells were lysed by ice-cold 
RIPA buffer containing 150 mM NaCl, 1 mM 
EDTA, 1% (v/v) NP-40, 0.25% (w/v) sodium 
deoxycholate, 1 mM PMSF, and protease inhibi-
Figure 1. Cell proliferation of MHCC-97L cells. Cells 
were treated with increasing concentrations of evero-
limus under normoxic, hypoxic or hypoxic condition 
with 6 μM cisplatin. Cell proliferation was analyzed 
by MTT assay. Data were presented as means ± SD 
from three independent experiments. 
Figure 2. Cellular apoptosis of MHCC-97L cells. Cells 
were treated with Control: in normoxic condition 
(20% O2, 5% CO2 and 75% N2) without any drug treat-
ment, Hypoxia: in hypoxic condition (1% O2, 5% CO2 
and 94% N2), Hypoxia + C: in hypoxic condition and 
6 μM cisplatin, Hypoxia + E: in hypoxic condition and 
10 nM everolimus, and Hypoxia + C + E: in hypoxic 
condition, 6 μM cisplatin and 10 nM everolimus. The 
percentage of apoptotic cells were the percentage of 
annexin V positive cells analyzed by flow cytometry. 
Data were presented as means ± SD from three in-
dependent experiments and statistical analysis were 
performed by one-way ANOVA. *P<0.05 versus Con-
trol. #P<0.05 of Hypoxia + C + E versus Hypoxia, Hy-
poxia + C or Hypoxia + E.
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tor cocktail (Roche Diagnostics, Penzbery, 
Germany) in 50 mM Tris-HCl buffer, pH 7.4. 
Equal amount of protein was loaded onto a 
10% SDS-polyacrylamide gel under reducing 
condition and transferred to PVDF membrane 
(Amersham Bioscience, Piscataway, NJ). Blots 
were probed with HIF-1α (Novus Biologicals, 
Littleton, CO), VEGF (Santa Cruz Biotechnology) 
and β actin (Sigma) overnight at 4°C. After 
washing, membranes were incubated with 
horseradish peroxidase-conjugated secondary 
antibodies (DAKO) and visualized using an 
enhanced chemiluminescence detection sys-
tem (ECL Plus) (Amersham) according to the 
manufacturer’s instructions.
In vivo orthotopic mouse HCC model
All the animal experiments were approved by 
the Committee on the Use of Live Animals in 
Figure 3. Tube formation ability of HUVEC cells. 
Cells were treated with Control: in normoxic con-
dition (20% O2, 5% CO2 and 75% N2) without any 
drug treatment, Hypoxia: in hypoxic condition (1% 
O2, 5% CO2 and 94% N2), Hypoxia + C: in hypoxic 
condition and 6 μM cisplatin, Hypoxia + E: in hy-
poxic condition and 10 nM everolimus, and Hy-
poxia + C + E: in hypoxic condition, 6 μM cisplatin 
and 10 nM everolimus. Upper panel: Representa-
tive fluorescence images (magnification: 400 ×) 
of tube formation of cells in Geltrex™ Reduced 
Growth Factor Basement Membrane Matrix. Lower 
panel: Bar chart presenting the tube area (number 
of pixels) of HUVEC cells under different treatment. 
Data were presented as means ± SD from three 
independent experiments and statistical analysis 
were performed by one-way ANOVA. *P<0.05 ver-
sus Control. #P<0.05 of Hypoxia + C + E versus Hy-
poxia or Hypoxia + C.
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Teaching and Research of The University of 
Hong Kong. Male CB17 severe combined immu-
nodeficient (SCID) mice of four to six weeks old 
were used and maintained in laminar flow cabi-
nets under pathogen-free condition. Subcu- 
taneous tumors were first grown by injecting 
MHCC97L cells (1 × 106) in a 0.2 ml culture 
medium subcutaneously into the right flank of 
mice. Once the subcutaneous tumors reached 
0.8-1 cm in diameter, mice were sacrificed and 
tumors were removed and cut into 2 mm3 
cubes, which were then implanted into the left 
liver lobes of another group of SCID mice. Six 
days after tumor implantation, the animals 
were randomly divided into five groups: 1) 
sham operation (Control; n=5), 2) hepatic artery 
ligation (HAL; n=5), 3) hepatic artery ligation 
combined with portal vein injection of cisplatin 
(3 mg/kg) (HAL + C; n=5), 4) hepatic artery liga-
tion combined with oral feeding of everolimus 
daily (10 mg/kg) (HAL + E), and 5) HAL com-
bined with portal vein injection of cisplatin (3 
mg/kg) and oral feeding of everolimus daily (10 
mg/kg) (HAL + C + E; n=5). Mice were sacrificed 
on day 25. Under anesthesia, D-luciferin (Life 
Technologies) was injected i.p. and the biolumi-
nescence signal was detected by the IVIS imag-
ing system 100 (Xenogen). An elliptical region 
of interest (ROI) was placed over the tumors 
and the total signal in the ROI (photons per sec-
ond) was quantified using the Living Image soft-
and dehydrated through a series of ethanol and 
xylenes. Slides were then examined with light 
microscope (100 ×) and single endothelial cells 
or clusters of endothelial cells positive for CD31 
staining were considered as a vessel. MVD was 
measured based on the Weidner’s method [21] 
by two independent investigators who were 
blinded to the study groups.
Statistical analysis
Data were presented as means ± SD from three 
independent experiments for the in vitro study 
and from n=5 for the in vivo study. Data were 
statistically analyzed with one-way ANOVA. 
Survival analysis was done by Mantel-Cox (Log-
Rank) test. All analysis was performed by Prism 
5.0 and data were considered statistically sig-
nificant at P<0.05. 
Results
Anti-proliferative effect of combined treatment 
with Hypoxia + C + E
The effect of different treatments on cell prolif-
eration was first measured by the MTT cell pro-
liferation assay (Figure 1). Cell proliferation 
decreased with increasing concentrations of 
everolimus under all the treatment condition. 
Without the addition of everolimus, treatment 
Figure 4. Expression of phosphorylated proteins in the Akt/mTOR signaling 
pathway. MHCC-97L cells were treated with Control: in normoxic condition (20% 
O2, 5% CO2 and 75% N2) without any drug treatment, Hypoxia: in hypoxic con-
dition (1% O2, 5% CO2 and 94% N2), Hypoxia + C: in hypoxic condition and 6 
μM cisplatin, Hypoxia + E: in hypoxic condition and 10 nM everolimus, and Hy-
poxia + C + E: in hypoxic condition, 6 μM cisplatin and 10 nM everolimus. The 
expressions of phosphorylated mTOR, p70S6, RPS6, Akt, TSC2, GSK3α and 
GSK3β were measured by the multiplex bead assay. The expression of GAPDH 
was used as internal control. Data were presented as means ± SD from three 
independent experiments and statistical analysis were performed by one-way 
ANOVA. *P<0.05 versus Control. #P<0.05 of Hypoxia + C + E versus Hypoxia, 
Hypoxia + C or Hypoxia + E.
ware (Xenogen). Liver were 
dissected, fixed in 10% for-
malin, and paraffin-embed-
ded for further analysis. This 
animal model was repeated 
and overall survival was 
monitor for 80 days for the 
toxicity test of each treat- 
ment. 
Microvessel density (MVD) 
measurement
After antigen retrieval of the 
liver sections, slides were 
incubated with anti-CD31 
antibody (Thermo Scientific, 
Waltham, MA) overnight at 
4°C and signal was detected 
by the LSAB + System-HRP 
kits (Dako) according to the 
manufacturer’s instruction. 
Sections were then counter-
stained with hematoxylin 
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of cells under hypoxic condition and under 
hypoxic condition with 6 μM cisplatin reduced 
the cell proliferation by 59.7% and 65.1%, 
respectively, when compared with that treated 
under normoxic condition. The IC50 under nor-
moxia, hypoxia and hypoxia with cisplatin were 
11.2 nM, 11.6 nM and 12.2 nM, respectively. 
With the addition of 10 nM everolimus, treat-
ment of cell under hypoxic condition with 6 μM 
cisplatin significantly reduced the cell prolifera-
tion by 64.0% and 39.2% when compared with 
that treated under normoxic condition and 
hypoxic condition, respectively. This suggested 
that 10 nM everolimus is the optimized concen-
tration in enhancing the anti-proliferating effect 
of single treatment.
Inhibiting effect of the combined treatment 
with Hypoxia + C + E on tube formation ability 
of HUVEC cells
Treatment with Hypoxia significantly enhanced 
the tube formation ability of HUVEC cells by 
40.0% when compared with the Control (Figure 
3). For the combined treatment with Hypoxia + 
C + E, the tube formation ability of HUVEC cells 
decreased by 52.0% when compared with the 
treatment with Hypoxia, and by 46.7% when 
compared with the treatment with Hypoxia + C. 
This suggested that combined treatment with 
Hypoxia + C + E was significant in reducing tube 
formation ability of HUVEC cells when com-
pared with the single treatments.
Figure 5. Western blotting analysis of the expression of HIF-1α and VEGF. 
MHCC-97L cells were treated with Control: in normoxic condition (20% O2, 5% 
CO2 and 75% N2) without any drug treatment, Hypoxia: in hypoxic condition (1% 
O2, 5% CO2 and 94% N2), Hypoxia + C: in hypoxic condition and 6 μM cisplatin, 
Hypoxia + E: in hypoxic condition and 10 nM everolimus, and Hypoxia + C + 
E: in hypoxic condition, 6 μM cisplatin and 10 nM everolimus. Upper panel: 
Representative blots of the expression of HIF-1α and VEGF were shown. The 
expression level of β-actin was used as the loading control. Lower panel: Bar 
chart presenting the ratio of HIF-1α vs. β-actin and VEGF vs. β-actin was shown. 
Data were presented as means ± SD from three independent experiments and 
statistical analysis were performed by one-way ANOVA. *P<0.05 versus Control. 
#P<0.05 of Hypoxia + C + E versus Hypoxia or Hypoxia + C.
Apoptotic effect of the 
combined treatment with 
Hypoxia + C + E
We then determined the 
apoptotic effect of different 
treatments with the annexin 
V assay (Figure 2). Treatment 
of cells with Hypoxia, Hypoxia 
+ C and Hypoxia + E signifi-
cantly increased the per-
centage of apoptotic cells by 
3.01 folds, 3.89 folds and 
2.33 folds, respectively, 
when compared with the 
Control. For the combined 
treatment with Hypoxia + C + 
E, the percentage of apop-
totic cells increased by 11.4 
folds when compared with 
the Control. In addition, trea- 
tment with Hypoxia + C + E 
further increased the per-
centage of apoptotic cells by 
3.78 folds when compared 
with the treatment with 
Hypoxia, by 2.93 folds when 
compared with the treat-
ment with Hypoxia + C, and 
by 4.89 folds when com-
pared with the treatment 
with Hypoxia + E treatment. 
This suggested that com-
bined treatment with Hypo- 
xia + C + E was significant in 
enhancing cellular apoptosis 
when compared with the sin-
gle treatment.
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Inhibiting effect of the combined treatment 
with Hypoxia + C + E on Akt/mTOR signaling 
pathway
Phosphoprotein alteration was analyzed using 
the MILLIPLEX MAP 8-Plex Multi-Pathway 
Signaling Phosphoprotein Kit (Figure 4). 
Phosphorylation of different targets/effectors 
of the Akt/mTOR pathway including p70S6, 
RPS6, Akt, TSC2, GSK3α and GSK3β was stud-
ied and each single treatment caused a signifi-
cant down-regulation of the Akt/mTOR signal-
ing pathway when compared with the Control. 
In addition, the combined treatment with 
Hypoxia + C + E further reduced the levels of 
these phosphorylated proteins. These results 
Figure 6. Tumor growth and progression of the mouse orthotopic model. Six days after tumor implantation, the 
animals were randomly divided into five groups: (1) sham operation (Control; n=5), (2) hepatic artery ligation alone 
(HAL; n=5), (3) hepatic artery ligation combined with portal vein injection of cisplatin (3 mg/kg) (HAL + C; n=5), (4) 
hepatic artery ligation combined with oral feeding of everolimus daily (10 mg/kg) (HAL + E) and (5) hepatic artery 
ligation combined with portal vein injection of cisplatin (3 mg/kg) and oral feeding of everolimus daily (10 mg/kg) 
(HAL + C + E; n=5). A. Mice were sacrificed on day 25. Tumor growth was monitor and the average bioluminescence 
signals detected against days after tumor implantation were plotted. Data were presented as means ± SEM and 
statistical analysis were performed by one-way ANOVA. *P<0.05 versus Control. #P<0.05 of HAL + C + E versus HAL 
or HAL + C. B. Mice with tumors from MHCC97L cells were shown. C. Representing gross images of the liver from 
each group were shown. D. Animal survival of each group was analyzed by log-rank test. 
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suggested a more potent inhibitory effect on 
the Akt/mTOR signaling pathway was observed 
in the combined treatment with Hypoxia + C + E 
than that of the single treatments. 
Combined treatment with Hypoxia + C + E was 
effective in degrading hypoxia-induced HIF-1α 
expression
When compared with the Control, induced 
expression of HIF-1α was found in the treat-
ment groups of Hypoxia by 2.34 folds and 
Hypoxia + C by 88.0% (Figure 5). Combined 
treatment with Hypoxia + C + E was found to 
reduce HIF-1α expression significantly by 2.66 
folds when compared with the treatment with 
Hypoxia, and by 2.14 folds when compared 
with the treatment with Hypoxia + C. This 
change in expression pattern was also found in 
VEGF expression. When compared with the 
Control, induced expression of VEGF was found 
in the treatment groups of Hypoxia by 16.2% 
and Hypoxia + C by 19.5%. Combined treat-
ment with Hypoxia + C + E was found to reduce 
Figure 7. Immunohistochemistry of CD-31 ex-
pression and the MVD analysis. The MVD mea-
surement in the tumor of each liver section by 
CD31 expression. Upper panel: Representing im-
ages of the CD-31 staining (magnification: 100 
×) of tumor in the liver section from each group 
were shown. Lower panel: the average MVD mea-
surements were plotted. Data were presented 
as means ± SD and statistical analysis were 
performed by one-way ANOVA. *P<0.05 versus 
Control. #P<0.05 of HAL + C + E versus HAL or 
HAL + C.
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HIF-1α expression significantly by 29.5% when 
compared with the treatment with Hypoxia, and 
by 13.9% when compared with the treatment 
with Hypoxia + C. This suggested that com-
bined treatment with Hypoxia + C + E was effec-
tive in degrading HIF-1α, which in turn reduced 
VEGF expression.
Anti-tumor effect of the combined treatment 
with HAL + C + E
An in vivo orthotopic mouse model was used to 
demonstrate the anti-tumor effect of different 
treatments. Measurement of bioluminescence 
signal was done on day 6, day 10, day 15 and 
day 25 after orthotopic tumor implantation 
(Figure 6A-C). Longitudinal monitoring of tumor 
growth showed that significant inhibition of 
tumor growth and progression occurred in all 
the treatment groups starting on Day 15. In 
addition, a more pronounced anti-tumor effect 
was shown in the group with combined treat-
ment with HAL + C + E when compared with the 
treatment group with HAL and HAL + C. The sur-
vival analysis was also performed to study the 
toxicity effect of different treatments (Figure 
6D). Combined treatment with HAL + C + E sig-
nificantly enhanced the overall survival from 40 
days in the control group to 67.5 days in the 
HAL + C + E group.
To examine the effect of different treatments 
on microvascular density (MVD) in tumors, 
blood vessels expressing CD31 were counted 
(Figure 7). Treatment with HAL and HAL + C sig-
nificantly enhanced angiogenesis with an 
increase in MVD by 2.63 folds and 2.78 folds, 
respectively, when compared with the Control 
group. For the group with combined treatment 
with HAL + C + E, MVD reduced by 8.27 folds 
when compared with the HAL group, and 8.73 
folds when compared with the HAL + C group. 
These results suggested that combined treat-
ment with HAL + C + E was more effective in 
inhibiting tumor growth and progression when 
compared with single treatments. In addition, 
treatment with HAL + C + E was effective in 
inhibiting hypoxia induced microvascular 
growth which makes the combined treatment a 
more potent treatment in reducing tumor size 
in this in vivo study. 
Discussion
TACE is one of the effective treatments in 
advanced HCC with the simultaneous actions 
of blocking blood supply and administration of 
a high dose of chemotherapeutic agent to the 
tumor. However, one of the side effects of TACE 
is the introduction of hypoxic condition, which 
in turn activates hypoxia-induced survival path-
ways and enhances VEGF-induced neovascu-
larization by stabilizing HIF-1α expression. A 
clinical study demonstrated that increases in 
neovascularization factors, VEGF and basic 
fibroblast growth factor (b-FGF), were found in 
non-responders of TACE treatment and VEGF 
was even singled out as an independent predic-
tor of survival [22]. Another study on TACE also 
demonstrated that the residual surviving can-
cerous tissue in HCC after TACE was highly vas-
cularized and TACE increased VEGF expression 
in the residual surviving cancerous tissue [23]. 
In addition, enhanced invasion of tumor and 
distant metastasis after hepatic artery ligation 
in orthotopic HCC mouse models were reported 
[24, 25]. These studies suggested that neovas-
cularization is one of the most crucial obstacles 
affecting the response of TACE in HCC patients.
Everolimus is a potent mTOR inhibitor. Previous 
studies have provided evidence that the Akt/
mTOR pathway is not only important for the sur-
vival of tumor cells but also for angiogenesis of 
tumor under hypoxia [26]. Studies demonstrat-
ed that mTOR is a positive regulator of HIF-1 
dependent gene transcription in cells exposed 
to hypoxia [27]. HIF1-α plays an important role 
in the up-regulation of certain hypoxia-related 
proteins involved in angiogenesis, such as 
VEGF, and in the inhibition of apoptosis [28]. 
HIF1-α has also been reported to interact with 
Akt to mediate hypoxia-induced chemoresis-
tance of cisplatin [29]. Therefore, blocking the 
Akt/mTOR/HIF-1 pathway by everolimus was 
expected to enhance the TACE efficacy in this 
study. 
Our previous study showed that single treat-
ment with everolimus inhibited HCC tumor 
growth and enhanced the sensitivity of HCC 
tumor cells to cisplatin-induced cytotoxicity 
[30]. In this study, we demonstrated that evero-
limus significantly enhanced the therapeutic 
efficacy of TACE using the in vitro and in vivo 
orthotopic mouse model. We showed that 
everolimus in combined with TACE significantly 
suppressed cell proliferation and enhanced 
cellular apoptosis in MHCC97L cells when com-
pared with single TACE treatment or hypoxia 
treatment. In addition, the combined treatment 
was effective in inhibiting tube formation of 
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HUVEC cells. This is supported by the inactiva-
tion of the Akt/mTOR signaling pathway with 
the decrease in phosphorylated p70S6, RPS6, 
Akt, TSC2, GSK3α and GSK3β expressions and 
the reduction in HIF-1α and VEGF expression. 
In conclusion, by blocking the Akt/mTOR signal-
ing pathway, everolimus enhanced the thera-
peutic efficacy of TACE. Based on this preclini-
cal study, the potential of combining everolimus 
with TACE was guaranteed which suggested the 
use of the combination therapy in the clinical 
treatment of advanced HCC patients. 
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